Market Research Logo

Osteoporosis - Pipeline Review, H1 2015

Osteoporosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2015’, provides an overview of the Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteoporosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteoporosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Osteoporosis Overview
Therapeutics Development
Pipeline Products for Osteoporosis - Overview
Pipeline Products for Osteoporosis - Comparative Analysis
Osteoporosis - Therapeutics under Development by Companies
Osteoporosis - Therapeutics under Investigation by Universities/Institutes
Osteoporosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Osteoporosis - Products under Development by Companies
Osteoporosis - Products under Investigation by Universities/Institutes
Osteoporosis - Companies Involved in Therapeutics Development
Abiogen Pharma S.p.A.
Ablynx NV
Alethia Biotherapeutics Inc.
Alize Pharma SAS
Alkem Laboratories Ltd.
Amgen Inc.
Amura Holdings Limited
Arcarios BV
Astellas Pharma Inc.
Bone Medical Limited
Bone Therapeutics SA
Caladrius Biosciences, Inc.
Chronos Therapeutics Limited
Chugai Pharmaceutical Co., Ltd.
Corium International, Inc.
Critical Pharmaceuticals Limited
Daiichi Sankyo Company, Limited
ElexoPharm GmbH
Eli Lilly and Company
EndoCeutics, Inc.
Ensoltek Co., Ltd.
Enzo Biochem, Inc.
F. Hoffmann-La Roche Ltd.
Galapagos NV
Glide Pharmaceutical Technologies Limited
Hanmi Pharmaceuticals, Co. Ltd.
Haoma Medica Ltd.
IMMD Inc.
Immunovo BV
Inbiopro Solutions Pvt. Ltd.
Kaken Pharmaceutical Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Lead Discovery Center GmbH
Lupin Limited
Medivir AB
Merck & Co., Inc.
Merrion Pharmaceuticals Plc
Novartis AG
Omeros Corporation
Oncobiologics, Inc.
Oscotec Inc.
Osteologix Holdings Plc
Pantarhei Bioscience BV
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
PhytoHealth Corporation
PolyNovo Limited
R-Pharm
Radius Health, Inc.
Richter Gedeon Nyrt.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shin Poong Pharm.Co., Ltd.
STELIS Biopharma Pvt. Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
TAmiRNA GmbH
TSRL, Inc.
Uni-Bio Science Group Ltd.
Unigene Laboratories, Inc.
Ventria Bioscience
Wroclawskie Centrum Badan EIT+ Sp. z o.o.
Zydus Cadila Healthcare Limited
Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aceclofenac + eperisone) - Drug Profile
AB-25E9 - Drug Profile
abaloparatide - Drug Profile
alendronate sodium - Drug Profile
alendronate sodium - Drug Profile
alendronate sodium - Drug Profile
ALX-0141 - Drug Profile
AM-3701 - Drug Profile
AOD-9604 - Drug Profile
ARC-205 - Drug Profile
AS-2690168 - Drug Profile
astrogorgiadiol - Drug Profile
bazedoxifene acetate - Drug Profile
Biosimilar for Osteoporosis - Drug Profile
blosozumab - Drug Profile
BN-005 - Drug Profile
BN-008 - Drug Profile
calcitonin - Drug Profile
CDR-914K058 - Drug Profile
CDRI-99/373 - Drug Profile
CH-5036249 - Drug Profile
denosumab - Drug Profile
denosumab biosimilar - Drug Profile
denosumab biosimilar - Drug Profile
Drug to Inhibit miR-31 for Osteoporosis - Drug Profile
Drug to Target miR-002 for Osteoporosis - Drug Profile
Drugs for Osteoporosis - Drug Profile
Drugs for Postmenopausal Osteoporosis - Drug Profile
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
DS-1501 - Drug Profile
esterol - Drug Profile
Eu-232 - Drug Profile
genipin - Drug Profile
I-HBD1 - Drug Profile
ibandronate sodium - Drug Profile
IBPB-008IG - Drug Profile
IMD-2560 - Drug Profile
IPS-02 Series - Drug Profile
K-671 - Drug Profile
MAb-7 - Drug Profile
MIV-711 - Drug Profile
Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis - Drug Profile
Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile
MOR-106 - Drug Profile
NBS-101 - Drug Profile
NEP-28 - Drug Profile
neridronic acid - Drug Profile
OCT-1547 - Drug Profile
odanacatib - Drug Profile
ODS-656 - Drug Profile
Oratonin - Drug Profile
OXY-149 - Drug Profile
Peniel-3000 - Drug Profile
PHN-031 - Drug Profile
poncirin - Drug Profile
prasterone + acolbifene hydrochloride - Drug Profile
PREOB - Drug Profile
Protein 1 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
Protein 2 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
Protein 3 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
Proteins to Inhibit RANKL for Breast Cancer and Osteoporosis - Drug Profile
PTH-CBD - Drug Profile
RDC-5 - Drug Profile
Recombinant Protein for Osteoporosis - Drug Profile
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile
Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis - Drug Profile
romosozumab - Drug Profile
RPH-203 - Drug Profile
S-007-1500 - Drug Profile
S-101479 - Drug Profile
S-49288 - Drug Profile
SBL-001 - Drug Profile
Small Molecule to Agonize LRP for Osteoporosis - Drug Profile
Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile
Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile
Small Molecule to Modulate Estrogen Receptor for Breast Cancer and Osteoporosis - Drug Profile
Small Molecule to Target LGR4 for Cancer and Osteoporosis - Drug Profile
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile
Small Molecules for Osteopenia and Osteoporosis - Drug Profile
Small Molecules for Osteoporosis - Drug Profile
Small Molecules for Osteoporosis - Drug Profile
Small Molecules for Primary Juvenile Osteoporosis - Drug Profile
Small Molecules to Activate CB2 for Osteoporosis - Drug Profile
Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis - Drug Profile
Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
Small Molecules to Target Androgen Receptor for Osteoporosis - Drug Profile
Sodium Quinate - Drug Profile
SP-35454 - Drug Profile
SR-2595 - Drug Profile
Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
TAK-075 - Drug Profile
teriparatide - Drug Profile
teriparatide - Drug Profile
teriparatide - Drug Profile
teriparatide - Drug Profile
teriparatide - Drug Profile
teriparatide acetate - Drug Profile
teriparatide biosimilar - Drug Profile
teriparatide biosimilar - Drug Profile
Vaccine to Target Sclerostin for Osteoporosis - Drug Profile
VEN-130 - Drug Profile
VS-105 - Drug Profile
VS-401 - Drug Profile
VS-411 - Drug Profile
zoledronic acid - Drug Profile
Osteoporosis - Recent Pipeline Updates
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Osteoporosis, H1 2015
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Osteoporosis - Pipeline by Abiogen Pharma S.p.A., H1 2015
Osteoporosis - Pipeline by Ablynx NV, H1 2015
Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H1 2015
Osteoporosis - Pipeline by Alize Pharma SAS, H1 2015
Osteoporosis - Pipeline by Alkem Laboratories Ltd., H1 2015
Osteoporosis - Pipeline by Amgen Inc., H1 2015
Osteoporosis - Pipeline by Amura Holdings Limited, H1 2015
Osteoporosis - Pipeline by Arcarios BV, H1 2015
Osteoporosis - Pipeline by Astellas Pharma Inc., H1 2015
Osteoporosis - Pipeline by Bone Medical Limited, H1 2015
Osteoporosis - Pipeline by Bone Therapeutics SA, H1 2015
Osteoporosis - Pipeline by Caladrius Biosciences, Inc. , H1 2015
Osteoporosis - Pipeline by Chronos Therapeutics Limited, H1 2015
Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015
Osteoporosis - Pipeline by Corium International, Inc., H1 2015
Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H1 2015
Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2015
Osteoporosis - Pipeline by Eli Lilly and Company, H1 2015
Osteoporosis - Pipeline by EndoCeutics, Inc., H1 2015
Osteoporosis - Pipeline by Ensoltek Co., Ltd., H1 2015
Osteoporosis - Pipeline by Enzo Biochem, Inc., H1 2015
Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Osteoporosis - Pipeline by Galapagos NV, H1 2015
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2015
Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Osteoporosis - Pipeline by Haoma Medica Ltd., H1 2015
Osteoporosis - Pipeline by IMMD Inc., H1 2015
Osteoporosis - Pipeline by Immunovo BV, H1 2015
Osteoporosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015
Osteoporosis - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2015
Osteoporosis - Pipeline by Lupin Limited, H1 2015
Osteoporosis - Pipeline by Medivir AB, H1 2015
Osteoporosis - Pipeline by Merck & Co., Inc., H1 2015
Osteoporosis - Pipeline by Merrion Pharmaceuticals Plc, H1 2015
Osteoporosis - Pipeline by Novartis AG, H1 2015
Osteoporosis - Pipeline by Omeros Corporation, H1 2015
Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2015
Osteoporosis - Pipeline by Oscotec Inc., H1 2015
Osteoporosis - Pipeline by Osteologix Holdings Plc, H1 2015
Osteoporosis - Pipeline by Pantarhei Bioscience BV, H1 2015
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015
Osteoporosis - Pipeline by Pfizer Inc., H1 2015
Osteoporosis - Pipeline by PhytoHealth Corporation, H1 2015
Osteoporosis - Pipeline by PolyNovo Limited, H1 2015
Osteoporosis - Pipeline by R-Pharm, H1 2015
Osteoporosis - Pipeline by Radius Health, Inc., H1 2015
Osteoporosis - Pipeline by Richter Gedeon Nyrt., H1 2015
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015
Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H1 2015
Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2015
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Osteoporosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Osteoporosis - Pipeline by TAmiRNA GmbH, H1 2015
Osteoporosis - Pipeline by TSRL, Inc., H1 2015
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H1 2015
Osteoporosis - Pipeline by Unigene Laboratories, Inc., H1 2015
Osteoporosis - Pipeline by Ventria Bioscience, H1 2015
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2015
Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2015
Osteoporosis - Dormant Projects, H1 2015
Osteoporosis - Dormant Projects (Contd..1), H1 2015
Osteoporosis - Dormant Projects (Contd..2), H1 2015
Osteoporosis - Dormant Projects (Contd..3), H1 2015
Osteoporosis - Dormant Projects (Contd..4), H1 2015
Osteoporosis - Dormant Projects (Contd..5), H1 2015
Osteoporosis - Dormant Projects (Contd..6), H1 2015
Osteoporosis - Dormant Projects (Contd..7), H1 2015
Osteoporosis - Dormant Projects (Contd..8), H1 2015
Osteoporosis - Discontinued Products, H1 2015
Osteoporosis - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Osteoporosis, H1 2015
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report